1-2 of 2
Yujin Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Yujin Xu, Baiqiang Dong, Weiguo Zhu, Jiancheng Li, Rong Huang, Zongwen Sun, Xinmei Yang, Liping Liu, Han He, Zhongxing Liao, Ni Guan, Yue Kong, Wanwei Wang, Jianxiang Chen, Huijuan He, Guoqin Qiu, Ming Zeng, Juan Pu, Wangyuan Hu, Yong Bao, Zhigang Liu, Jun Ma, Hao Jiang, Xianghui Du, Jin Hu, Tingting Zhuang, Jing Cai, Jin Huang, Hua Tao, Yuan Liu, Xiaodong Liang, Juying Zhou, Guangzhou Tao, Xiao Zheng, Ming Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1792–1799.
https://doi.org/10.1158/1078-0432.CCR-21-3843
Published: 02 May 2022
View article titled, A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma
Open the PDF for A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

Ying Jin, Yamei Chen, Huarong Tang, Xiao Hu, Shawna M. Hubert, Qian Li, Dan Su, Haimiao Xu, Yun Fan, Xinmin Yu, Qixun Chen, Jinshi Liu, Wei Hong, Yujin Xu, Huan Deng, Dapeng Zhu, Pansong Li, Yuhua Gong, Xuefeng Xia, Carl M. Gay, Jianjun Zhang, Ming Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 526–539.
https://doi.org/10.1158/1078-0432.CCR-21-1943
Published: 01 February 2022
View article titled, Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Open the PDF for Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer in another window
Includes: Supplementary data